The purpose of this study is to evaluate whether telemonitoring of patients with chronic heart failure produces a reduction in the combined end point of all cause mortality and number of hospitalisations, and whether it improves health related quality of life. In addition, the trials evaluate the economic and organisational impact of the telemonitoring service and examine its acceptability by patients and health professionals.
The purpose of this study is to the evaluate the use of a mobile and PSTN phone-based telehealth platform will be able to produce a reduction in the combined end point of all cause mortality, will have positive or negative impact in their generic and disease specific quality of life , or their specific activity compared with usual care. Following this; it is also hypothesized that this will also lead to a change in overall risk for CHF complications. In addition the patients' satisfaction using the telemedicine service will be studied. A Cost-Effective Analysis and Cost Utility Analysis will evaluate the tele-health service compared with the usual care from the health and social perspective.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Enrollment
60
Patients in the intervention group receive a personal 1-lead or 12-lead ECG recorder, a blood pressure monitor, a digital weight scale and appropriate education regarding the use of these devices. ThA trained nurse visits the patients weekly during the first month, and monthly thereafter, to confirm the appropriate use of the devices and services, to monitor symptoms, adherence to pharmacological and non-pharmacological treatment, and to complete the case record forms when necessary. If there is deterioration in the monitored vital signs, or if symptoms are reported, the allocated cardiologist is informed via the telehealth platform and has to decide whether the patient has to visit the hospital as in- or outpatient and whether the therapy has to be modified.
Cardiology Department - Regional University Hospital of Larisa
Larissa, Thessaly, Greece
Combined end point of all cause mortality
Time frame: 12 months minimum
Number of hospitalisations for heart failure
Time frame: 12 months minimum
Cardiovascular and all-cause mortality
Time frame: 12 months minimum
Health related quality of life as measured by the SF-36 v2
Time frame: 12 months minimum- at the entry point of the intervention and the end
Patient's specific activity using Specific activity questionnaire (SAQ) and the Veterans specific activity questionnaire (VSAQ)
Time frame: 12 months minimum- at the entry point of the intervention and the end.
Disease Specific Quality of Life using the Minnesota Living with Heart Failure questionnaire (MLHF)
Time frame: 12 months minimum- at the entry point of the intervention and the end.
Economic Evaluation (Cost-Effective Analysis- Cost Utility Analysis)
Time frame: 12 months minimum
Patients' Acceptance-Satisfaction measured by the WSD Questionnaire
Time frame: at 2nd and at 12th month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.